Combining smoking-cessation support with low-dose CT lung screening
Integrating Smoking Cessation With Low-dose CT-screening for Lung Cancer - a Randomized Study
This project tries to see if combining low-dose CT scans with smoking-cessation support (a smartphone app or written materials) helps people aged 50–74 who still smoke quit and find lung cancer earlier.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1200 (estimated) |
| Ages | 50 Years to 74 Years |
| Sex | All |
| Sponsor | Oulu University Hospital Academic / other |
| Locations | 5 sites (Helsinki and 4 other locations) |
| Trial ID | NCT07331519 on ClinicalTrials.gov |
What this trial studies
This is a prospective, randomized study that assigns current heavy smokers aged 50–74 to one of three groups: low-dose CT (LDCT) plus a smartphone smoking-cessation app, LDCT plus written cessation materials, or the smartphone app without LDCT. The trial compares quit rates between the cessation methods and examines whether LDCT changes the stage distribution and lung-cancer-specific survival. Participants must be current smokers with defined pack-year histories and have smartphone access. The study is conducted at multiple university hospitals in Finland with follow-up for lung cancer outcomes and survival.
Who should consider this trial
Good fit: Ideal candidates are current smokers aged 50–74 with a substantial long-term smoking history who can use a smartphone and are willing to attend study visits at a participating hospital.
Not a fit: People with a prior diagnosis of melanoma, lung, renal, or breast cancer, a chest CT within the past year, no smartphone access, or major psychiatric/substance-use issues that limit participation are unlikely to benefit from this trial.
Why it matters
Potential benefit: If successful, the approach could increase smoking-cessation rates and detect lung cancers at earlier stages, potentially improving lung-cancer-specific survival.
How similar studies have performed: LDCT screening has been shown to reduce lung-cancer mortality and smoking-cessation programs improve outcomes, but combining LDCT with smartphone-based cessation support is less well-studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Able to provide written informed consent 2. Age between 50-74 3. Smoked ≥ 15 cigarettes/day for ≥ 25 years or smoked ≥ 10 cigarettes/day for ≥ 30 years and are active smokers (smoking during the last two weeks) 4. Access to a smartphone (iPhone or Android) Exclusion Criteria: 1. Current or past melanoma, lung, renal or breast cancer 2. A chest CT examination less than one year before inclusion 3. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial 4. No access to a smartphone (iPhone or Android) 5. Participant is unwilling or unable to comply with treatment and trial instructions 6. Any condition that study investigators consider an impediment to safe trial participation
Where this trial is running
Helsinki and 4 other locations
- Helsinki University Hospital — Helsinki, Finland (Not_yet_recruiting)
- Oulu University Hospital — Oulu, Finland (Recruiting)
- Tampere University Hospital — Tampere, Finland (Not_yet_recruiting)
- Turku University Hospital — Turku, Finland (Not_yet_recruiting)
- Vaasa Central Hospital — Vaasa, Finland (Not_yet_recruiting)
Study contacts
- Study coordinator: Jussi P Koivunen, MD, PhD
- Email: jussi.koivunen@pohde.fi
- Phone: +358504182666
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.